Mostrar el registro sencillo del ítem
dc.contributor.author | Ruiz, Susana | |
dc.contributor.author | Domenech, Mirian | |
dc.contributor.author | Antequera, María Luisa | |
dc.contributor.author | García, Pedro | |
dc.contributor.author | García, Ernesto | |
dc.contributor.author | Corsini, Bruno | |
dc.contributor.author | Aguinagalde, Leire | |
dc.contributor.author | Fenoll, Asuncion | |
dc.contributor.author | Yuste, Jose Enrique | |
dc.date.accessioned | 2020-06-11T09:21:39Z | |
dc.date.available | 2020-06-11T09:21:39Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Vaccine. 2016 Dec 7;34(50):6148-6157. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/10341 | |
dc.description.abstract | The cell wall glucosaminidase LytB of Streptococcus pneumoniae is a surface exposed protein involved in daughter cell separation, biofilm formation and contributes to different aspects of the pathogenesis process. In this study we have characterized the antibody responses after immunization of mice with LytB in the presence of alhydrogel as an adjuvant. Enzyme-linked immunosorbent assays measuring different subclasses of immunoglobulin G, demonstrated that the antibody responses to LytB were predominantly IgG1 and IgG2b, followed by IgG3 and IgG2a subclasses. Complement-mediated immunity against two different pneumococcal serotypes was investigated using sera from immunized mice. Immunization with LytB increased the recognition of S. pneumoniae by complement components C1q and C3b demonstrating that anti-LytB antibodies trigger activation of the classical pathway. Phagocytosis assays showed that serum containing antibodies to LytB stimulates neutrophil-mediated phagocytosis against S. pneumoniae. Animal models of infection including invasive pneumonia and sepsis were performed with two different clinical isolates. Vaccination with LytB increased bacterial clearance and induced protection demonstrating that LytB might be a good candidate to be considered in a future protein-based vaccine against S. pneumoniae. | es_ES |
dc.description.sponsorship | This work was supported by grants SAF2012-39444-C01/02 from Ministerio de Economía y Competitividad (MINECO). Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) is an initiative of ISCIII. BC and LA were supported, respectively, by a fellowship from the Brazilian Program Ciencia Sem Fronteiras (CsF) from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and by an FPI fellowship from MINECO. The authors wish to thank Sandra Martín for technical assistance | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | AM | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.mesh | Phagocytosis | es_ES |
dc.subject.mesh | Adjuvants, Immunologic | es_ES |
dc.subject.mesh | Aluminum Hydroxide | es_ES |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Antibodies, Bacterial | es_ES |
dc.subject.mesh | Complement System Proteins | es_ES |
dc.subject.mesh | Disease Models, Animal | es_ES |
dc.subject.mesh | Enzyme-Linked Immunosorbent Assay | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Immunoglobulin G | es_ES |
dc.subject.mesh | Immunologic Factors | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Mice, Inbred BALB C | es_ES |
dc.subject.mesh | N-Acetylmuramoyl-L-alanine Amidase | es_ES |
dc.subject.mesh | Neutrophils | es_ES |
dc.subject.mesh | Pneumococcal Infections | es_ES |
dc.subject.mesh | Pneumococcal Vaccines | es_ES |
dc.subject.mesh | Pneumonia, Bacterial | es_ES |
dc.subject.mesh | Sepsis | es_ES |
dc.subject.mesh | Streptococcus pneumoniae | es_ES |
dc.subject.mesh | Treatment Outcome | es_ES |
dc.title | Immunization with LytB protein of Streptococcus pneumoniae activates complement-mediated phagocytosis and induces protection against pneumonia and sepsis | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 27840016 | es_ES |
dc.format.volume | 34 | es_ES |
dc.format.number | 50 | es_ES |
dc.format.page | 6148-6157 | es_ES |
dc.identifier.doi | 10.1016/j.vaccine.2016.11.001 | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
dc.contributor.funder | Centro de Investigación Biomedica en Red - CIBER | |
dc.contributor.funder | National Council for Scientific and Technological Development (Brasil) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1873-2518 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.vaccine.2016.11.001 | es_ES |
dc.identifier.journal | Vaccine | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/SAF2012-39444-C01/02 | es_ES |
dc.rights.accessRights | open access | es_ES |